Shin Nippon Biomedical Laboratories

17 articles about Shin Nippon Biomedical Laboratories

• 

  Satsuma Fails to Secure FDA Approval for Nasal Powder Migraine Drug

  1/18/2024

  The FDA’s Complete Response Letter identified problems with the drug candidate’s chemistry, manufacturing and controls, parent company Shin Nippon Biomedical Laboratories announced Thursday.

• Satsuma Pharmaceuticals and SNBL Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society’s 65th Annual Scientific Meeting

  6/15/2023

  Satsuma Pharmaceuticals, Inc., and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd., announced that three abstracts describing efficacy and safety results from the STS101 Phase 3 efficacy trial were selected for presentation at the American Headache Society’s 65th Annual Scientific Meeting.

• SNBL to Acquire Satsuma Pharmaceuticals

  4/16/2023

  Satsuma Pharmaceuticals, Inc. announced that it has entered into a definitive agreement to be acquired by Shin Nippon Biomedical Laboratories, Ltd. for $0.91 in cash per share at the closing of the transaction plus one non-tradeable contingent value right of up to $5.77 per share.

• Evidera and CSS Collaborate to Develop Joint Real-world and Patient-centered Research Capabilities in Japan

  8/21/2019

  Evidera, a business unit of Pharmaceutical Product Development, LLC (PPD), has entered into an exclusive collaboration agreement with Clinical Study Support, Inc. (CSS), a subsidiary of Shin Nippon Biomedical Laboratories Ltd. (SNBL), extending both organizations’ capabilities to deliver more robust consulting and analytical capabilities and creating a more complete geographic customer solution for clinical, real-world and patient-centered research.

• Pharmaron LLC Acquires U.S. Phase I/II Clinical CRO From Shin Nippon Biomedical Laboratories

  3/1/2017

• Satsuma Pharma Spins Out From Shin Nippon Biomedical Laboratories With Funding From Leading Institutional Life Science Investors

  1/5/2017

• ISA Pharmaceuticals Signs R&D Agreement With Shin Nippon Biomedical Laboratories

  3/3/2015

• PPD, Inc. And Shin Nippon Biomedical Laboratories Announce Japanese Clinical Development Joint Venture And Additional Collaborations

  12/29/2014

• Transcept Pharmaceuticals, Inc. and Shin Nippon Biomedical Laboratories Announce Global Licensing Agreement for Advanced Acute Migraine Treatment

  9/26/2013

• Shin Nippon Biomedical Laboratories Release: Novel Nasal Epinephrine Shows Comparable Absorption to EpiPen® in a Feasibility Study

  9/10/2013

• Results of Shin Nippon Biomedical Laboratories First Phase I Clinical Study for Intranasal Zolmitriptan Formulation (Migraine Drug)

  4/6/2012

• Shin Nippon Biomedical Laboratories Release: First Report on Results of US Phase 2 Clinical Study of Intranasal Granisetron

  8/4/2009

• Shin Nippon Biomedical Laboratories Agrees Licensing Nasal Drug Delivery Technology To Tokai Pharmaceuticals

  8/4/2006

• Shin Nippon Biomedical Laboratories And Takeda Pharmaceutical Co. Ltd. Successfully Complete Joint Research On Cynomolgus Monkey

  6/26/2006

• Shin Nippon Biomedical Laboratories Obtains New Knowledge On Drug-Metabolizing Enzyme Cytochrome P450

  5/10/2006

• Japanese Firm Plans To Invest $20M In City

  10/3/2005

• Tranzyme Pharma And Shin Nippon Biomedical Laboratories To Collaborate In The Development Of Non-Human Primate Models Of Human Disease

  4/15/2004